Global Influenza Vaccines Market and Forecasts 2024 – 2032

January 2024 | 310 pages | ID: G8A78B0E1789EN
DPI Research

Abstracts

The global influenza vaccines market size was valued at USD 7.8 Billion in 2023 and is likely to reach USD 13.7 Billion in 2032, expanding at a CAGR 7.2% during the forecast period.

Several factors are contributing to the growth of the influenza vaccines market. Here are some key factors:

• Increasing Awareness and Education
• Government Initiatives and Vaccination Programs
• Rising Incidence of Influenza
• Advancements in Vaccine Technology
• Increased Healthcare Spending
• Expanding Target Population
• Globalization and Travel
• Growing Geriatric Population
• Public Health Preparedness
• Collaborations and Partnerships
• Regulatory Support

“Global Influenza Vaccines Market and Forecasts 2024 – 2032” presents an in-depth assessment of the global influenza vaccines market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global influenza vaccines market. The report also provides up-to-date historical market size data for the period 2018 – 2023 and an illustrative forecast to 2032 covering key market aspects like market value, volume analysis, and trends for influenza vaccines globally.

The report contains a deep analysis of the global influenza vaccines market with size in terms of both value and volume. The report provides a clear insight into current and future developments of the global influenza vaccines market. The report also explores a detailed analysis of the children and adults vaccinated with influenza vaccines globally from 2018-

2023 and forecasts to 2032. It provides essential insights into influenza vaccines market revenue for the top 27 regional and national, and forecast until 2032.

Key trends in terms of collaboration deals, merger & acquisitions, distribution, exclusive and licensing agreement are analyzed with details. The report also offers detailed information about the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase. The report also investigates detailed insights about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU, and Japan. The report also delivers a detailed assessment of the latest happenings in the influenza vaccines market globally. The report also examines the main market growth driving and challenges forces and also gives an all-round future outlook through 2032.

The report concludes with the profiles of the key players in the global influenza vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, promising vaccines in the clinical development, influenza vaccines sales value analysis, and recent development.

Other emerging players are making novel technology-based vaccines that are likely to affect the market share during the forecast period. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with phase, platform technology, and recent development.

The report will serve as a source for a 360-degree analysis in which various models will be thoroughly integrated. After a thorough study of the historical and current growth parameters, the growth prospects of the global influenza vaccines market are determined with utmost precision.

Key and Emerging Players in the Global Influenza Vaccines Market are Listed Below:

1. Sanofi Pasteur

2. GlaxoSmithKline (GSK)

3. Seqirus (CSL Limited)

4. AstraZeneca

5. Mylan(Viatris)

6. BioDiem

7. Novavax

8. Medicago

9. Moderna Inc

10. Pneumagen

11. Daiichi–Sankyo

12. Altimmune

13. FluGen

14. Imutex

15. EpiVax

16. Osivax

17. Emergex Vaccines

18. Versatope Therapeutics, Inc.

19. BIKEN Co., Ltd.

20. Gamma Vaccines Pty Ltd.

21. BiondVax Pharmaceuticals Ltd.

22. Hualan Biological Engineering Inc.

23. Shanghai Institute of Biological Products Co., Ltd.

The Report Analyses the Market on the Basis of Nationals and Presents the Forecast in Terms of Value and Volume for the Next 8 Years. Twenty-Seven Major Markets(27MM) Covered in the Report are as follows:

1. United States

2. Canada

3. Brazil

4. Germany

5. France

6. Italy

7. Spain

8. United Kingdom

9. Netherlands

10. Sweden

11. Denmark

12. Poland

13. Norway

14. Finland

15. Ireland

16. Belgium

17. Australia

18. New Zealand

19. Japan

20. China

21. India

22. South Korea

23. Thailand

24. Singapore

25. Hongkong

26. Malaysia

27. Indonesia

This Latest and Comprehensive th Global Influenza Vaccines Market Research Report 2024 provides:

• Comprehensive research methodology of the global influenza vaccines market
• Detailed and comprehensive market overview with important analyst insights
• Insights into the market determinants stimulating the global influenza vaccines market
• Analysis of the historical growth of the market size of the global influenza vaccines market from 2018 to 2023
• The global influenza vaccines market size estimation and forecast from 2024 to 2032 and growth rate up to 2032
• The market size of the 27 major influenza vaccines markets with eight years forecast
• High-Level assessment of the overall persons being vaccinated with influenza vaccines
• Scrutinizes the persons being vaccinated with influenza vaccines in the 27 major influenza vaccines markets with eight years forecast
• Detailed assessment of the most recent happenings in the global influenza vaccines market
• Comprehensive analysis of the regulatory framework including the approval process and an overview of the regulatory authorities in the United States, EU, and Japan
• Provides key trends with respect to collaboration deals, merger & acquisitions, distribution, exclusive and licensing agreement
• Detailed observations of the most recent clinical trials of the influenza vaccines
• A comprehensive list of the key players along with the analysis of their current vaccines portfolios, promising vaccines in the clinical development, sales value analysis, and recent development
• An insightful analysis of the emerging players along with the analysis of their promising vaccines in the clinical development, phase, platform technology, and recent development

This 2024 Report Helps Answer the Following Questions:

• What is the current size of the global influenza vaccines market?
• How big is the global market for influenza vaccines?
• How much will this market be worth between 2024 and 2032?
• How many persons being vaccinated with influenza vaccines globally during 2018 – 2032?
• Which country is the leader in the global market for influenza vaccines?
• How large is the market and what are the growth rates of the 27 most important markets for influenza vaccines?
• What is the regulatory framework of the global influenza vaccines market?
• What are the main drivers and challenges in the global influenza vaccines market?
• What are the major deals happenings in the global influenza vaccines market?
• Who are the top players and what are their activities, revenue, recent developments, and prospects?
• Who are the emerging players?
• What are some of the most prominent influenza vaccines currently in development?
• What are the activities, phase, platform technology, and recent developments of the emerging players?
• How will the industry develop in the forecast period 2024 – 2032?

Contents

1. INTRODUCTION


2. RESEARCH METHODOLOGY


3. EXECUTIVE SUMMARY


4. GLOBAL NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES AND FORECAST (2018 – 2032)


5. GLOBAL INFLUENZA VACCINES MARKET REVENUE AND FORECAST (2018 – 2032)


6. GLOBAL INFLUENZA VACCINES MARKET SHARE AND Y–O–Y GROWTH (%)

6.1 Number of Persons Vaccinated with Influenza Vaccines Share, 2018 – 2032 (%)
6.2 Influenza Vaccines Market Share,2018 - 2032(%)

7. GLOBAL INFLUENZA VACCINES MARKET DRIVERS AND CHALLENGES

7.1 Market Drivers
7.2 Market Challenges

8. GLOBAL INFLUENZA VACCINES MARKET, BY GEOGRAPHY (VOLUME AND VALUE),2018 – 2032

8.1 United States
  8.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
  8.1.2 United States Influenza Vaccines Market Revenue (2018 – 2032)
8.2 Canada
  8.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
  8.2.2 Canada Influenza Vaccines Market Revenue (2018 – 2032)
8.3 Germany
  8.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
  8.3.2 Germany Influenza Vaccines Market Revenue (2018 – 2032)
8.4 France
  8.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
  8.4.2 France Influenza Vaccines Market Revenue (2018 – 2032)
8.5 Italy
  8.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.5.2 Italy Influenza Vaccines Market Revenue (2018 – 2032)
8.6 Spain
  8.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.6.2 Spain Influenza Vaccines Market Revenue (2018 – 2032)
8.7 United Kingdom
  8.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.7.2 United Kingdom Influenza Vaccines Market Revenue (2018 – 2032)
8.8 Netherlands
  8.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.8.2 Netherlands Influenza Vaccines Market Revenue (2015 – 2027)
8.9 Sweden
  8.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.9.2 Sweden Influenza Vaccines Market Revenue (2018 – 2032)
8.10 Denmark
  8.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.10.2 Denmark Influenza Vaccines Market Revenue (2018 – 2032)
8.11 Poland
  8.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
  8.11.2 Poland Influenza Vaccines Market Revenue (2018 – 2032)
8.12 Norway
  8.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.12.2 Norway Influenza Vaccines Market Revenue (2018 – 2032)
8.13 Finland
  8.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032 )
  8.13.2 Finland Influenza Vaccines Market Revenue (2018 – 2032)
8.14 Ireland
  8.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.14.2 Ireland Influenza Vaccines Market Revenue (2018 – 2032)
8.15 Belgium
  8.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.15.2 Belgium Influenza Vaccines Market Revenue (2015 – 2027)
8.16 Australia
  8.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.16.2 Australia Influenza Vaccines Market Revenue (2018 – 2032)
8.17 New Zealand
  8.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.17.2 New Zealand Influenza Vaccines Market Revenue (2018 – 2032)
8.18 Japan
  8.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.18.2 Japan Influenza Vaccines Market Revenue (2018 – 2032)
8.19 Brazil
  8.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.19.2 Brazil Influenza Vaccines Market Revenue (2018 – 2032)
8.20 China
  8.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.20.2 China Influenza Vaccines Market Revenue (2018 – 2032)
8.21 India
  8.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.21.2 India Influenza Vaccines Market Revenue (2018 – 2032)
8.22 South Korea
  8.22.1 South Korea Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.22.2 South Korea Influenza Vaccines Market Revenue (2018 – 2032)
8.23 Thailand
  8.23.1 Thailand Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.23.2 Thailand Influenza Vaccines Market Revenue (2018 – 2032)
8.24 Singapore
  8.24.1 Singapore Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.24.2 Singapore Influenza Vaccines Market Revenue (2018 – 2032)
8.25 Hongkong
  8.25.1 Hongkong Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.25.2 Hongkong Influenza Vaccines Market Revenue (2018 – 2032)
8.26 Malaysia
  8.26.1 Malaysia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.26.2 Malaysia Influenza Vaccines Market Revenue (2018 – 2032)
8.27 Indonesia
  8.27.1 Indonesia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.27.2 Indonesia Influenza Vaccines Market Revenue (2018 – 2032)
8.28 Rest of the World (ROW)
  8.28.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
  8.28.2 ROW Influenza Vaccines Market Revenue (2018 – 2032)

9. RECENT DEVELOPMENT IN THE GLOBAL INFLUENZA VACCINES MARKET


10. REGULATORY FRAMEWORK OF THE GLOBAL INFLUENZA VACCINES MARKET

10.1 United States
10.2 Europe
10.3 Japan

11. MAJOR DEALS IN THE GLOBAL INFLUENZA VACCINES MARKET

11.1 Merger and Acquisitions
11.2 Collaboration Deals
11.3 Licensing Agreement
11.4 Exclusive Agreement
11.5 Distribution Agreement

12. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY

12.1 Year 2023
12.2 Year 2022

13. KEY COMPANIES ANALYSIS

13.1 Sanofi Pasteur
  13.1.1 Business Overview
  13.1.2 Influenza Vaccines Portfolio
  13.1.3 Influenza Vaccines Value Sales Analysis
  13.1.4 Promising Influenza Vaccines in the Clinical Development
  13.1.5 Recent Development
13.2 GlaxoSmithKline (GSK)
  13.2.1 Business Overview
  13.2.2 Influenza Vaccines Portfolio
  13.2.3 Influenza Vaccines Sales Value Analysis
  13.2.4 Recent Development
13.3 Seqirus (CSL Limited)
  13.3.1 Business Overview
  13.3.2 Influenza Vaccines Portfolios
  13.3.3 Influenza Vaccines Sales Value Analysis
  13.3.4 Promising Influenza Vaccines in the Clinical Development
  13.3.5 Recent Development
13.4 AstraZeneca
  13.4.1 Business Overview
  13.4.2 Influenza Vaccines Portfolio
  13.4.3 Influenza Vaccines Sales Value Analysis
  13.4.4 Recent Development
13.5 Gamma Vaccines Pty Ltd
  13.5.1 Business Overview
  13.5.2 Influenza Vaccines Portfolio
  13.5.3 Recent Development
13.6 Hualan Biological Engineering Inc
  13.6.1 Business Overview
  13.6.2 Influenza Vaccines Portfolio
  13.6.3 Recent Development
13.7 Shanghai Institute of Biological Products Co., Ltd.
  13.7.1 Business Overview
  13.7.2 Influenza Vaccines Portfolio
  13.7.3 Recent Development
13.8 Mylan
  13.8.1 Business Overview
  13.8.2 Influenza Vaccines Portfolio
  13.8.3 Recent Development
13.9 BioDiem
  13.9.1 Business Overview
  13.9.2 Influenza Vaccines Portfolio
  13.9.3 Recent Development
13.10 BIKEN Co., Ltd.
  13.10.1 Business Overview
  13.10.2 Influenza Vaccine Portfolio
  13.10.3 Recent Development

14. EMERGING PLAYERS

14.1 Novavax
  14.1.1 Business Overview
  14.1.2 Promising Influenza Vaccines in the Clinical Development
  14.1.3 Recent Development
14.2 BiondVax Pharmaceuticals Ltd.
  14.2.1 Business Overview
  14.2.2 Promising Influenza Vaccines in the Clinical Development
  14.2.3 Recent Development
14.3 Medicago
  14.3.1 Business Overview
  14.3.2 Promising Influenza Vaccines in the Clinical Development
  14.3.3 Recent Development
14.4 Moderna Inc
  14.4.1 Business Overview
  14.4.2 Promising Influenza Vaccines in the Clinical Development
  14.4.3 Recent Development
14.5 Pneumagen
  14.5.1 Business Overview
  14.5.2 Promising Influenza Vaccines in the Clinical Development
  14.5.3 Recent Development
14.6 Altimmune
  14.6.1 Business Overview
  14.6.2 Promising Influenza Vaccines in the Clinical Development
  14.6.3 Recent Development
14.7 Daiichi Sankyo
  14.7.1 Business Overview
  14.7.2 Promising Influenza Vaccines in the Clinical Development
  14.7.3 Recent Development
14.8 FluGen
  14.8.1 Business Overview
  14.8.2 Promising Influenza Vaccines in the Clinical Development
  14.8.3 Recent Development
14.9 Imutex
  14.9.1 Business Overview
  14.9.2 Promising Vaccines in the Clinical Development
  14.9.3 Recent Development
14.10 EpiVax
  14.10.1 Business Overview
  14.10.2 Promising Influenza Vaccines in the Clinical Development
  14.10.3 Recent Development
14.11 Versatope Therapeutics, Inc.
  14.11.1 Business Overview
  14.11.2 Promising Influenza Vaccines in the Clinical Development
  14.11.3 Recent Development
14.12 Emergex Vaccines
  14.12.1 Business Overview
  14.12.2 Promising Influenza Vaccines in the Clinical Development
  14.12.3 Recent Development
14.13 Osivax
  14.13.1 Business Overview
  14.13.2 Promising Influenza Vaccines in the Clinical Development
  14.13.3 Recent Development

15. APPENDIX

15.1 About DPI Research
15.2 Glossary of Terms

List Of Tables

LIST OF TABLES:

Table 6-1: Global Number of Persons Vaccinated with Influenza Vaccines Share (Percent),2018 – 2032
Table 6-2: Global Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent),2024 – 2032
Table 6-3: Global Influenza Vaccines Market Share (Percent),2018 – 2023
Table 6-4: Global Influenza Vaccines Market Share Forecast (Percent),2023 – 2032
Table 10-1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 10-2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 10-3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 11-1: Merger & Acquisitions in the Influenza Vaccines Market
Table 11-2: Collaboration Deal in the Influenza Vaccines Market
Table 11-3: Licensing Agreement in the Influenza Vaccines Market
Table 11-4: Exclusive Agreement in the Influenza Vaccines Market
Table 11-5: Distribution Agreement in the Influenza Vaccines Market
Table 13-1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 13-2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 14-1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 14-2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 14-3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 14-4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 14-5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 14-6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 14-7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 14-8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 14-9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 14-10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 14-11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
List of Figures:
Figure 4-1: Global Number of Persons Vaccinated with Influenza Vaccines (Thousand),2018 – 2023
Figure 4-2: Global Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2024 – 2032
Figure 5-1: Global Influenza Vaccines Market (Million US$),2018 – 2023
Figure 5-2: Global Influenza Vaccines Market Forecast (Million US$),2024 – 2032
Figure 8-1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-3: United States Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-4: United States Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-7: Canada Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-8: Canada Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-11: Germany Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-12: Germany Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-15: France Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-16: France Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-19: Italy Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-20: Italy Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-23: Spain Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-24: Spain Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-27: United Kingdom Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-31: Netherlands Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-35: Sweden Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-36: Sweden Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-39: Denmark Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-40: Denmark Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-43: Poland Influenza Vaccines Revenue Market (Million US$),2018 – 2023
Figure 8-44: Poland Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-47: Norway Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-48: Norway Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-51: Finland Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-52: Finland Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-55: Ireland Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-56: Ireland Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-59: Belgium Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-60: Belgium Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-63: Australia Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-64: Australia Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-67: New Zealand Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-71: Japan Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-72: Japan Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2023 – 2032
Figure 8-75: Brazil Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-76: Brazil Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8 77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-79: China Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-80: China Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-83: India Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-84: India Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-85: South Korea Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-86: South Korea Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-87: South Korea Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-88: South Korea Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-89: Thailand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-90: Thailand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-91: Thailand Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-92: Thailand Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-93: Singapore Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-94: Singapore Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-95: Singapore Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-96: Singapore Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-97: Hongkong Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-98: Hongkong Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-99: Hongkong Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-100: Hongkong Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-101: Malaysia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-102: Malaysia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-103: Malaysia Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-104: Malaysia Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-105: Indonesia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-106: Indonesia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-107: Indonesia Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-108: Indonesia Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 8-109: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023
Figure 8-110: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032
Figure 8-111: ROW Influenza Vaccines Market Revenue (Million US$),2018 – 2023
Figure 8-112: ROW Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032
Figure 13-1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2018 – 2023
Figure 13-2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2024 – 2032
Figure 13-3: GSK Influenza Vaccines Net Sales Value (Million US$),2018 – 2023
Figure 13-4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2024 – 2032
Figure 13-5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2018 – 2023
Figure 13-6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2024 – 2032
Figure 13-7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2018 – 2023
Figure 13-8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2024 – 2032